International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(9), P. 4077 - 4077
Published: April 25, 2025
The
recent
introduction
of
the
term
metabolic-dysfunction-associated
steatotic
liver
disease
(MASLD)
has
highlighted
critical
role
metabolism
in
disease’s
pathophysiology.
This
innovative
nomenclature
signifies
a
shift
from
previous
designation
non-alcoholic
fatty
(NAFLD),
emphasizing
condition’s
progressive
nature.
Simultaneously,
MASLD
become
one
most
prevalent
diseases
worldwide,
highlighting
urgent
need
for
research
to
elucidate
its
etiology
and
develop
effective
treatment
strategies.
review
examines
delineates
revised
definition
MASLD,
exploring
epidemiology
pathological
changes
occurring
at
various
stages
disease.
Additionally,
it
identifies
metabolically
relevant
targets
within
provides
summary
latest
targeted
drugs
under
development,
including
those
clinical
some
preclinical
stages.
finishes
with
look
ahead
future
therapy
goal
summarizing
providing
fresh
ideas
insights.
Diagnostics,
Journal Year:
2025,
Volume and Issue:
15(5), P. 641 - 641
Published: March 6, 2025
Background:
In
the
literature,
there
is
no
study
investigating
relationship
between
thyroid
hormones
in
pregnancies
at
41
weeks
and
above
birth
timing,
labor
duration,
frequency
of
fetal
distress,
premature
rupture
membranes
(PROM),
maternal
hemogram
values.
Methods:
A
total
68
nulliparous
pregnant
women
who
were
admitted
to
Basaksehir
Cam
Sakura
City
Hospital
with
indications
delivery
August
2023
January
2024,
ages
20
38
comorbidities,
included
study.
Pregnant
≥41
gestation
classified
as
late-term
pregnancy
group
(n
=
37),
those
37
control
31).
The
thyrotropin
(TSH),
free
thyroxine
(FT4),
hemoglobin
levels
relevant
parameters
evaluated.
Results:
FT4
values
diagnosed
distress
entire
population
observed
be
statistically
significantly
lower
(p
<
0.05).
significant
negative
linear
was
detected
weights
newborns
It
determined
that,
decreased,
newborn
increased.
There
difference
two
groups
terms
TSH/FT4
values,
types,
or
postpartum
Hb/Htc
decrease
>
No
found
diagnosis
PROM,
amount
Conclusions:
may
important
mature
late-mature
periods
pregnancy.
an
association
risk,
type
birth,
weight.
Current Issues in Molecular Biology,
Journal Year:
2025,
Volume and Issue:
47(3), P. 154 - 154
Published: Feb. 27, 2025
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
and
its
progressive
form,
metabolic
steatohepatitis
(MASH),
represent
a
growing
global
health
problem
linked
to
obesity,
insulin
resistance,
dyslipidemia.
MASLD
often
leads
fibrosis,
cirrhosis,
hepatocellular
carcinoma.
Currently,
therapeutic
options
are
limited,
emphasizing
the
need
for
novel,
targeted
pharmacological
interventions.
Resmetirom,
selective
thyroid
hormone
receptor
beta
(THR-β)
agonist,
offers
promising
approach
by
specifically
enhancing
hepatic
metabolism
while
minimizing
systemic
effects.
Clinical
trials
have
demonstrated
capacity
reduce
triglyceride
accumulation
improve
lipid
profiles.
Early-
advanced-phase
studies,
including
MAESTRO
program,
highlight
significant
reductions
in
fat
content
favorable
impacts
on
noninvasive
biomarkers
of
fibrosis
with
minimal
side
This
review
highlights
evidence
from
pivotal
explores
resmetirom's
mechanism
action,
compares
efficacy
safety
other
emerging
agents.
While
resmetirom
marks
breakthrough
non-cirrhotic
MASH
management,
further
long-term
studies
essential
fully
evaluate
clinical
benefits
potential
regulatory
approval
broader
use
MASH.
Cells,
Journal Year:
2025,
Volume and Issue:
14(6), P. 428 - 428
Published: March 13, 2025
Hepatocellular
carcinoma
(HCC)
is
the
sixth
most
common
cancer
and
third
leading
cause
of
deaths
worldwide.
The
etiology
HCC
has
now
dramatically
changed
from
viral
hepatitis
to
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD).
main
pathogenesis
MASLD-related
hepatic
lipid
accumulation
hepatocytes,
which
causes
chronic
inflammation
subsequent
progression
fibrosis.
Chronic
generates
oxidative
stress
DNA
damage
in
contribute
genomic
instability,
resulting
development
HCC.
Several
molecular
pathways
are
also
linked
MASLD.
In
particular,
MAPK
PI3K-Akt-mTOR
upregulated
MASLD,
promoting
survival
proliferation
cells.
addition,
MASLD
been
reported
enhance
patients
with
infection.
Although
there
no
approved
medication
for
besides
resmetirom
USA,
some
preventive
strategies
onset
Sodium-glucose
cotransporter-2
(SGLT2)
inhibitor,
a
class
medications,
exert
anti-tumor
effects
on
by
regulating
reprogramming.
Moreover,
CD34-positive
cell
transplantation
improves
fibrosis
intrahepatic
angiogenesis
supplying
various
growth
factors.
Furthermore,
exercise
through
an
increase
energy
consumption
as
well
changes
chemokines
myokines.
this
review,
we
summarize
recent
progress
made
pathogenic
mechanisms
MASLD-associated
introduced
new
therapeutic
preventing
based
Frontiers in Medicine,
Journal Year:
2025,
Volume and Issue:
12
Published: March 25, 2025
Introduction
Pharmacotherapy
for
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
still
under
development
and
has
not
been
fully
established.
For
patients
with
MASLD
type
2
diabetes,
treatment
antidiabetic
drugs,
including
sodium–glucose
cotransporter
(SGLT2)
inhibitors,
recommended,
vitamin
E
supplementation
when
efficacy
insufficient.
The
benefits
risks
of
SGLT2
inhibitors
diabetes
have
thoroughly
investigated.
Objective
This
prospective
randomized
controlled
trial
aimed
to
elucidate
the
effectiveness
inhibitor
dapagliflozin
in
comparison
comorbid
diabetes.
Methods
enrolled
24
who
were
assigned
receive
either
(5
mg/day)
or
(150
weeks.
primary
outcomes
included
serum
levels
AST,
ALT,
γ-GT,
IV
collagen,
FIB-4
index.
secondary
BMI,
HbA1c
ferritin
levels,
lipid
profile,
body
composition
assessed
using
InBody,
hepatic
fat
content
fibrosis
evaluated
FibroScan.
Adverse
events
monitored
throughout
study
period.
Results
Both
groups
demonstrated
significant
reductions
AST
ALT
but
intergroup
differences
significant.
group
showed
additional
benefits,
decreases
BMI
HbA1c,
ferritin,
LDL
cholesterol,
indicating
improved
glycemic
control
profile.
Dapagliflozin
administration
was
associated
a
decline
skeletal
muscle
index,
risk
loss
absent
group.
reduction
mass
clinically
as
it
suggests
potential
worsened
overall
survival
treatment.
Conclusion
indicates
that
provides
several
enzymes
fat,
observed
decrease
adverse
effect
on
long-term
outcomes.
Muscle
should
be
receiving
therapy
mitigate
sarcopenia
progression
ensure
comprehensive
approach
management.
Clinical
registration
https://jrct.niph.go.jp/re/reports/detail/81182
,
identifier
jRCT1031180386.
